Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Pimethixene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.76 |
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.76 |
| ▸ | DRD1 known ✓ | P21728 | 5/20 | 0.76 |
| ▸ | ADRA1A known ✓ | P35348 | 4/20 | 0.76 |
| ▸ | KCNH2 known ✓ | Q12809 | 4/20 | 0.76 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.76 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.76 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.76 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.76 |
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A known ✓ | Q03164 | 3/20 | 0.63 |
| ▸ | HRH1 known ✓ | P35367 | 5/20 | 0.58 |
| ▸ | ADRA2B known ✓ | P18089 | 4/20 | 0.58 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.58 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.58 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.58 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.58 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.49 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.49 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimethixene SCHEMBL301225 | 1.00 | HTT (1.00) | HTTCYP3A4SETD7CHRM2ADRA2A | |
| Maleic Acid SCHEMBL11596646 | 0.90 | HTT (0.80) | HTTCYP3A4SETD7CHRM2ADRA2A | |
| Fumaric Acid SCHEMBL11596650 | 0.90 | HTT (0.80) | HTTCYP3A4SETD7CHRM2ADRA2A | |
| Pimethixene SCHEMBL29433731 | 0.87 | SETD7 (1.00) | HTTCYP3A4SETD7CHRM2ADRA2A | |
| Pimethixene SCHEMBL301596 | 0.87 | SETD7 (1.00) | HTTCYP3A4SETD7CHRM2ADRA2A | |
| Fumaric Acid SCHEMBL11574698 | 0.87 | CYP3A4 (0.76) | HTTCYP3A4SETD7CHRM2ADRA2A | |
| Fumaric Acid SCHEMBL11574700 | 0.87 | CYP3A4 (0.76) | HTTCYP3A4SETD7CHRM2ADRA2A | |
| SCHEMBL11580051 | 0.82 | HTT (0.70) | HTTCYP3A4SETD7CHRM2ADRA2A | |
| Hydrochloric Acid SCHEMBL11580044 | 0.81 | HTT (0.68) | HTTCYP3A4SETD7CHRM2ADRA2A | |
| SCHEMBL11157769 | 0.80 | SETD7 (0.68) | HTTCYP3A4SETD7CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| WO-2022124342-A1 | AGENT FOR CANCER THERAPY, AND SCREENING METHOD FOR ACTIVE INGREDIENT THEREOF | 国立大学法人 岡山大学 | 2022-06-16 | — | — | WO | claimed |
| CN-106265614-B | A kind of micromolecular inhibitor of Ebola's pseudovirus | 中国科学院上海巴斯德研究所 | 2019-07-19 | — | — | CN | claimed |
| CN-106265614-A | A kind of micromolecular inhibitor of Ebola's pseudovirus | 中国科学院上海巴斯德研究所 | 2017-01-04 | — | — | CN | claimed |
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260117282-A1 | High Throughput Cell-Based Screening For Aptamers | MEIRAGTX GENE REGULATION LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4696377-A2 | 5HT AGONISTS FOR TREATING DISORDERS | The Regents of the University of California (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4043016-B1 | THE 5HT AGONIST CLEMIZOLE FOR USE IN TREATING EPILEPSY DISORDERS | UNIV CALIFORNIA (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12447144-B2 | 5HT agonists for treating disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-21 | — | — | US | disclosed |
| US-12419866-B2 | Compounds and methods for treating an epileptic disorder | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| WO-2010011599-A2 | PIMETHIXENE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100021524-A1 | PIMETHIXENE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090203713-A1 | Hedgehog pathway antagonists to treat disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
| US-20090149545-A1 | TREATMENT OF CORONAVIRUS INFECTION | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-06-11 | — | — | US | disclosed |
| US-7544712-B1 | Treatment of coronavirus infection | NATIONAL HEALTH RESEARCH INSITUTES (TW) | 2009-06-09 | — | — | US | disclosed |
| US-7410975-B2 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20050119273-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119273-A1 | Small molecule toll-like receptor (TLR) antagonists | TLR3, TLR8, TLR7 | CHRM2 1453/4885ADRA2A 1099/4885DRD1 1595/4885 |
| US-12419866-B2 | Compounds and methods for treating an epileptic disorder | GABRE, SLC6A1, GABBR1 | CHRM2 940/4885ADRA2A 1339/4885DRD1 1525/4885 |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | TLR3, TLR8, TLR7 | CHRM2 1453/4885ADRA2A 1099/4885DRD1 1595/4885 |
| US-20100021524-A1 | PIMETHIXENE DERIVATIVES FOR PROMOTING BONE GROWTH | PGF, FGF23, PIM1 | CHRM2 4730/4885ADRA2A 3355/4885DRD1 4205/4885 |
| US-20260117282-A1 | High Throughput Cell-Based Screening For Aptamers | CPSF6, TIA1, UPF1 | CHRM2 4805/4885ADRA2A 4250/4885DRD1 3798/4885 |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | SLC6A4, SLC6A2, TPH2 | CHRM2 207/4885ADRA2A 144/4885DRD1 342/4885 |
| US-12447144-B2 | 5HT agonists for treating disorders | HTR1A, HTR5A, HTR2A | CHRM2 357/4885ADRA2A 37/4885DRD1 178/4885 |
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | SLC6A13, SLC6A11, SLC6A1 | CHRM2 1827/4885ADRA2A 1422/4885DRD1 1610/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | CHRM2 4445/4885ADRA2A 3359/4885DRD1 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.